Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
6869 On Other Exchanges
6869 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sysmex corp (6869) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SYSMEX CORP (6869)

Related News

No related news articles were found.

sysmex corp (6869) Related Businessweek News

No Related Businessweek News Found

sysmex corp (6869) Details

Sysmex Corporation, together with its subsidiaries, engages in the research and development, production, sale, service, and support of diagnostic instruments, reagents, and software worldwide. The company provides diagnostics products for use in the areas of hematology, hemostasis, immunochemistry, clinical chemistry, urinalysis, and others; and La-vietal LS, a clinical testing instrument system that links clinical testing instruments and other systems to provide an efficient operating environment. It also offers particle analyzer products, including FPIA-3000 Flow Particle Image Analyzer, which offers automated analysis of particle size and shape; FPIA-3000 Darkfield unit to analyze samples, such as drugs, mica, and biological cells; and XT-2000iV, an animal blood cell analysis software used in the hematological analysis of laboratory veterinary animals, such as rats, mice, or dogs. In addition, the company provides life sciences solutions comprising automated gene amplification detector, a system for the detection of lymph node metastasis based on the one-step nucleic acid amplification method used for the diagnosis of breast, colon, and stomach cancer lymph node diagnosis in hospitals and other facilities, as well as a laboratory testing service for research involving the risk of recurrence of breast cancer. Further, it offers ASTRIM FIT, a peripheral artery monitoring device that measures hemoglobin levels without blood sampling and is used in fitness centers and various other sites, as well as sells health management support software. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

5,903 Employees
Last Reported Date: 06/19/15
Founded in 1968

sysmex corp (6869) Top Compensated Officers

Chairman of the Managing Board, Chief Executi...
Total Annual Compensation: ¥139.0M
Compensation as of Fiscal Year 2014.

sysmex corp (6869) Key Developments

Sysmex Makes Top Quality Haematology Available for All at EuroMedLab, Paris

The Sysmex Corporation unveiled its latest series of haematology analysers at the annual IFCC congress, EuroMedLab JIB in Paris. The XN-L series follows in the footsteps of its game-changing big brother, the XN-Series. The new, smaller XN-L Series makes top quality haematology available for all. Sysmex is yet again changing the perspective in the field of haematology. Sysmex is also showing solutions in its other areas of expertise, including urinalysis, Point of Care and morphology. Due to its exclusive distribution rights, it has another game changer on show - the ultra-flexible intelligent lab automation provided by GLP systems. Another highlight is the introduction of a new solution in haemostasis, the CA-1600 with increased results security thanks to pre-analytical checks and incorporating coagulation, chromogenic and immunoassay methodologies.

LabCorp Signs Partnership with Sysmex to Develop Blood-Based Molecular Diagnostics for Tumours

Sysmex and LabCorp announced that it have signed a strategic collaboration to develop blood-based molecular diagnostic tests for use in oncology-related precision medicine. Under the agreement, the company will provide reagents and services to enable LabCorp subsidiary Covance to carry out OncoBEAM and Plasma Sequencing testing services to support cancer-related clinical trials. Furthermore, the company and LabCorp will explore opportunities to develop commercial applications for the company's technologies in clinical diagnostics. The company's OncoBEAM and Plasma Sequencing assays enable molecular genetic analysis of cell-free tumour DNA from blood samples, often referred to as "liquid biopsies". The technology would offer a non-invasive alternative to biopsies under specific circumstances, and are designed to determine a tumour's mutational status.

Sysmex Corp. and Laboratory Corp. of America Holdings Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products

Sysmex Corp. and Laboratory Corp. of America Holdings announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ strength in the development of innovative blood-based diagnostic solutions with LabCorp's unparalleled capabilities: global leadership in precision medicine through Covance Drug Development’s (Covance) extensive involvement in oncology clinical trials and a unique ability to commercialize clinically-relevant diagnostic tests through LabCorp Diagnostics as such applications are developed. The Sysmex OncoBEAM™ and Plasma Sequencing assays allow for molecular genetic analysis of cell-free tumor DNA from blood samples. These technologies, often referred to as liquid biopsies, provide non-invasive alternatives to biopsies under specific circumstances and are designed to determine the mutational status of a patient’s tumor. These highly-sensitive methods allow for the potential selection of appropriate therapeutic agents and, in some cases, may eliminate the need for further surgeries or biopsies. Moreover, blood-based diagnostic DNA tests can be performed when no tumor tissue is available and utilized to serially monitor tumor changes in patients over time or in response to therapeutic treatment. The OncoBEAM™ assays target a wide variety of clinically actionable genetic mutations in cancer and, along with sequencing-based evaluation of circulating tumor DNA through Plasma Sequencing, offer biopharmaceutical companies powerful tools for developing new therapeutic options. Under the terms of this collaboration, Sysmex Inostics will provide reagents and, when appropriate, services to enable Covance’s central laboratory to perform OncoBEAM™ and Plasma Sequencing testing services in its global locations to support oncology clinical trials. In addition, as clinical utility of these technologies is further characterized through ongoing clinical trials, the parties will evaluate opportunities to develop commercial applications for Sysmex’s technologies in clinical diagnostics.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6869:JP ¥7,300.00 JPY +40.00

6869 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $52.00 USD +0.03
Bio-Rad Laboratories Inc $150.79 USD +0.54
BioMerieux €95.90 EUR +0.51
Mindray Medical International Ltd $28.62 USD +0.354
PerkinElmer Inc $53.48 USD +0.65
View Industry Companies

Industry Analysis


Industry Average

Valuation 6869 Industry Range
Price/Earnings 55.0x
Price/Sales 6.6x
Price/Book 8.6x
Price/Cash Flow 55.0x
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYSMEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at